araag2/HINT huggingface dataset:
Clinical trial NCT02716818 (phase 3, status: completed)
Conditions: congenital adrenal hyperplasia
ICD codes: N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: chronocort®, standard glucocorticoid therapy
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          1. Known CAH due to 21-hydroxylase deficiency (classic CAH) diagnosed in childhood with
             documented (at any time) elevated 17-OHP and/or A4 and currently treated with
             hydrocortisone, prednisone, prednisolone or dexamethasone (or a combination of the
             aforementioned glucocorticoids) on a stable glucocorticoid therapy for a minimum of 6
             months.

          2. Provision of signed written informed consent.

          3. Non-pregnant, non-lactating females who are post menopausal, naturally or surgically
             sterile, or of childbearing potential with a negative urinary pregnancy test and using
             a medically acceptable method of contraception.

          4. Plasma renin activity (PRA) less than 1.5 times the upper limit of normal (ULN) at
             screening or within 3 months prior to screening, except in subjects who have been
             diagnosed with hypertension where the renin is not being used to monitor
             fludrocortisone replacement.

          5. Plasma renin activity (PRA) less than 1.5 times the upper limit of normal (ULN) at
             screening or within 3 months prior to screening, except in subjects who have been
             diagnosed with hypertension where the renin is not being used to monitor
             fludrocortisone replacement.

        Exclusion Criteria:

          1. Co-morbid condition requiring daily administration of a medication (or consumption of
             any material) that interferes with the metabolism of glucocorticoids.

          2. Clinical or biochemical evidence of hepatic or renal disease. Creatinine over twice
             the ULN or elevated liver function tests (ALT or AST >2 times the ULN).

          3. Subjects on regular daily inhaled, topical, nasal or oral steroids for any indication
             other than CAH.

          4. Subjects with any other significant medical or psychiatric conditions that in the
             opinion of the investigator would preclude participation in the trial.

          5. History of malignancy (other than basal cell carcinoma successfully treated >6 months
             prior to entry into the study).

          6. Participation in another clinical trial of an investigational or licensed drug or
             device within the 3 months prior to inclusion in this study.

          7. Subjects with a history of bilateral adrenalectomy.

          8. Subjects having previously been exposed to Chronocort®.

          9. Subjects unable to comply with the requirements of the protocol.
Clinical trial NCT02717195 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: risperidone, olanzapine, lu af35700, lu af35700
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  The patient has schizophrenia, diagnosed according to DSM-5(TM) (Diagnostic and
             Statistical Manual of Mental Disorders) and confirmed by the Mini International
             Neuropsychiatric Interview for Schizophrenia and Psychotic Disorders

          -  The patient is either an inpatient at a psychiatric setting or outpatient consulting a
             psychiatrist.

          -  Patients should be treated with adequate dose(s) and agent(s) of antipsychotic
             treatment for at least 2 weeks prior to Screening

          -  The patient has failed to show an adequate response in the level of psychotic symptoms
             despite at least one documented treatment trial with an adequate dose of an
             antipsychotic agent prescribed for an adequate time (at least lasting for 6 weeks)
             during 2 years prior to Screening. The failure to respond to the current antipsychotic
             treatment trial may be considered a retrospective failed treatment, if the patient was
             treated for 6 weeks with adequate dose(s) and agent(s)

          -  The patient has a PANSS total score of ≥80 and a score of ≥4 on at least 2 of the
             following PANSS items (at Screening and at the first visit of Period A)

          -  The patient has a CGI-S score of ≥4 at Screening and at the first visit of Period A

        Exclusion Criteria:

          -  The patient has any current primary psychiatric disorder other than schizophrenia as
             assessed by the Mini International Neuropsychiatric Interview (MINI)

          -  The patient is experiencing an acute exacerbation of his/her psychotic symptoms

          -  The patient has not responded to treatment with clozapine

        Other protocol defined inclusion and exclusion criteria may apply
Clinical trial NCT02718326 (phase 3, status: completed)
Conditions: nonproliferative diabetic retinopathy
ICD codes: E10.3213, E10.3293, E10.3313, E10.3393, E10.3413, E10.3493, E11.3213
Drugs: intravitreal aflibercept injection [iai], sham
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Key Inclusion Criteria:

          1. Men or women ≥18 years of age with type 1 or 2 diabetes mellitus who have moderately
             severe to severe nonproliferative diabetic retinopathy (NPDR) [(diabetic retinopathy
             severity scale (DRSS) levels 47 or 53)], confirmed by the central reading center, in
             whom panretinal photocoagulation (PRP) can be safely deferred for at least 6 months
             per the investigator

          2. Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS)
             letter score in the study eye of ≥69 letters (approximate Snellen equivalent of 20/40
             or better)

        Key Exclusion Criteria:

          1. Presence of diabetic macular edema (DME) threatening the center of the macula in the
             study eye

          2. Evidence of retinal neovascularization on clinical examination or Fluorescein
             Angiography (FA)

          3. Any prior focal or grid laser photocoagulation or any prior PRP in the study eye

          4. Any prior systemic anti-vascular endothelial growth factor (VEGF) treatment or
             intravitreal (IVT) anti-VEGF treatment in the study eye

          5. Any prior intraocular steroid injection in the study eye

          6. Current anterior segment neovascularization (ASNV), vitreous hemorrhage, or tractional
             retinal detachment visible at the screening assessments in the study eye

        Note: Other inclusion/ exclusion criteria apply
Clinical trial NCT02718417 (phase 3, status: terminated)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: carboplatin, paclitaxel, avelumab, avelumab
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1, NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1
Reason stopped: 
    the study was terminated based on the results of a planned interim analysis that showed
    futility of efficacy.
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  Histologically confirmed Stage III-IV epithelial ovarian, fallopian tube, or primary
             peritoneal cancer, including malignant mixed Müllerian tumors with high grade serous
             component

          -  Patients must be candidates for platinum based chemotherapy and previously untreated

          -  Patients must have completed a surgical debulking procedure, or be candidates for
             neoadjuvant chemotherapy

          -  Availability of an archival formalin fixed, paraffin embedded (FFPE) tumor tissue
             block or a minimum of 15 slides

          -  ECOG PS 0-1

          -  Adequate hematological, renal, and liver function

        Key Exclusion Criteria:

          -  Non epithelial tumors or ovarian tumors with low malignant potential (ie, borderline
             tumors) or mucinous tumors

          -  Prior systemic anti-cancer treatment for EOC, FTC, or PPC including prior
             immunotherapy with IL 2, IFN α, or anti PD 1, anti PD L1, anti PD L2, anti CD137, or
             anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA 4) antibody (including
             ipilimumab), or any other antibody or drug specifically targeting T cell co
             stimulation or immune checkpoint pathways

          -  Patients for whom, in the opinion of the Investigator, there is clinical benefit to
             administer bevacizumab as a first-line treatment and for whom bevacizumab is approved
             and available in this setting.

          -  Cancer for which intraperitoneal cytotoxic chemotherapy is planned

          -  Active autoimmune disease (some exceptions include diabetes type I, vitiligo,
             psoriasis, hypo- or hyperthyroidism not requiring immunosuppressive treatment)
Clinical trial NCT02718898 (phase 3, status: completed)
Conditions: genital psoriasis, psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50, L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: ixekizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have chronic plaque psoriasis based on a diagnosis of chronic plaque psoriasis for at
             least 6 months before baseline.

          -  Have moderate-to-severe psoriasis in the genital area at screening and baseline.

          -  Have plaque psoriasis in a nongenital area at screening and baseline.

          -  Have failed to respond to, or are intolerant of, at least 1 topical therapy used for
             treatment of psoriasis affecting the genital area.

          -  Must agree to use reliable method of birth control, which could include abstinence,
             during the study and for at least 12 weeks following the last dose of study drug.

        Exclusion Criteria:

          -  Pustular, erythrodermic, and/or guttate forms of psoriasis.

          -  History of drug-induced psoriasis.

          -  Have recently received certain treatments for psoriasis (in particular, within the
             past 4 weeks but the restriction can go up to 12 months for some treatments).

          -  Have ever received treatment with ixekizumab, secukinumab, brodalumab, or another drug
             with a similar mode of action.

          -  Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks
             prior to baseline and during the study.

          -  Are currently enrolled in any other clinical trial involving an investigational
             product.

          -  Serious disorder or illness other than plaque psoriasis.

          -  Active or history of malignant disease within 5 years prior to baseline.

          -  Serious infection within the last 3 months.

          -  Have received a live vaccine within 3 months of baseline or plan to do so during the
             study.

          -  Have received a vaccination with Bacillus Calmette-Guérin (BCG) within the past year.

          -  Pregnant or breastfeeding (lactating) women.
Clinical trial NCT02721966 (phase 3, status: completed)
Conditions: axial psoratic arthritis
ICD codes: A01.04, A02.23, A39.83, A39.84, A54.42, B06.82, B26.85
Drugs: secukinumab and placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent must be obtained before any assessment is performed

          -  Diagnosis of psoriatic arthritis classified by Classification criteria for psoriatic
             arthritis (CASPAR) criteria

          -  Active spinal disease defined by Bath ankylosing spondylitis disease activity index
             (BASDAI) score ≥ 4

          -  Spinal Pain visual analog scale (VAS) ≥ 40 (on a VAS 100 scale)

          -  Inadequate Response to at least 2 non-steroidal anti-inflammatory drugs over a 4 weeks
             period

        Exclusion Criteria:

          -  History of exposure to other IL-17 or IL-23 inhibitor biologic drug

          -  History of exposure to previous biologic disease modifying anti-rheumatic drugs
             (DMARDs) (Tumor necrosis factor (TNF) blockers or Ustekinumab)

          -  Current treatment with disease modifying anti-rheumatic drugs (DMARDs) other than
             Methotrexate

          -  Subjects taking high potency opioid analgesics (e.g. methadone, hydromorphone,
             morphine)

          -  Chest X-ray or chest magnetic resonance imaging (MRI) with evidence of ongoing
             infectious or malignant process, obtained within 3 months prior to screening and
             evaluated by a qualified physician

        Other protocol-defined inclusion and exclusion criteria may have applied.
Clinical trial NCT02722837 (phase 3, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: sof/vel
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  HCV RNA ≥ 10^4 IU/mL at screening

          -  Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy

        Key Exclusion Criteria:

          -  Any other chronic liver disease

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  Clinical hepatic decompensation

          -  Prior exposure to SOF or other nucleotide analogue HCV NS5B inhibitor or any HCV NS5A
             inhibitor

        Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Clinical trial NCT02725008 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: dexamethasone, placebo
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of asthma defined as at least two (2) prior episodes of respiratory illness
             characterized by wheezing treated with inhaled beta agonists

        Exclusion Criteria:

          -  pregnancy

          -  severe chronic cardiac, respiratory, neurological or neuromuscular disease

          -  complete resolution of symptoms after one treatment of beta agonists

          -  severe asthma symptoms as defined by a Pulmonary Index Score of 12 or greater
Clinical trial NCT02727751 (phase 3, status: completed)
Conditions: constipation predominant irritable bowel syndrome
ICD codes: K59.00, K59.09, K59.01, K59.02, K59.03, K59.04, K58.1
Drugs: tenapanor
SMILES: CN1C[C@@H](C2=CC(=CC=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC(=CC=C2)[C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)C2=C(C1)C(Cl)=CC(Cl)=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects completed all 16 weeks of TEN-01-301 or all 26 weeks of TEN-01-302

          -  Subject demonstrated adequate compliance with the study procedures during either the
             TEN-01-301 or TEN-01-302 studies

          -  Females must be of non-childbearing potential; If of child-bearing potential, must
             have negative pregnancy test and confirm the use of one of the appropriate means of
             contraception

          -  Males must agree to use appropriate methods of barrier contraception or have
             documented surgical sterilization

        Exclusion Criteria:

          -  Subject has been withdrawn or discontinued prematurely from either TEN-01-301 or
             TEN-01-302

          -  The subject reports using any prohibited medication and is not willing to abide by the
             restrictions for intake

          -  Pregnant or lactating women
Clinical trial NCT02727881 (phase 3, status: unknown status)
Conditions: age-related macular degeneration
ICD codes: H35.3130, H35.3230, H35.3110, H35.3120, H35.3131, H35.3132, H35.3190
Drugs: squalamine lactate ophthalmic solution, 0.2%, placebo ophthalmic solution, ranibizumab
SMILES: CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)NCCCNCCCCN)OS(O)(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 50 years

          -  A diagnosis of choroid neovascularization (CNV) secondary to AMD with CNV comprising
             at least 50% of the total lesion area on fluorescein angiography (FA)

          -  Central subfield thickness (spectral domain (SD)-OCT central 1 mm) of ≥ 300 μm

          -  Best-corrected visual acuity (BCVA) 20/40 to 20/320 (73- to 24-letter score on the
             Early Treatment of Diabetic Retinopathy Study [ETDRS] chart)

        Exclusion Criteria:

          -  Neovascularization secondary to any other condition than AMD in the study eye; Blood
             occupying greater than 50% of the AMD lesion, or blood > 1.0 sq. mm underlying the
             fovea

          -  Pigment epithelial detachment (PED) without associated subretinal fluid and/or cystic
             retinal changes

          -  Clinical evidence of diabetic retinopathy or diabetic macular edema in the study eye

          -  Confounding ocular conditions in the study eye which will affect interpretation of
             OCT, VA or assessment of macular appearance (e.g., cataract, epiretinal membrane,
             retinal vascular occlusive disease)

          -  Fibrosis or atrophy, retinal epithelial tear in the center of the fovea in the study
             eye or any condition preventing VA improvement

          -  Uncontrolled glaucoma in the study eye, or currently receiving topical glaucoma
             medication in the study eye
Clinical trial NCT02738138 (phase 3, status: completed)
Conditions: hepatitis c virus infection, human immunodeficiency virus infection, chronic hepatitis c, compensated cirrhosis and non-cirrhotics
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2, Z21, B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4, K74.3, K74.4, K74.5, K74.60, K74.69, P78.81, K70.30
Drugs: abt-493 coformulated with abt-530
SMILES: CC(C)(C)[C@@H]1NC(=O)O[C@@H]2CCC[C@H]2OC\C=C\C(F)(F)C2=NC3=C(C=CC=C3)N=C2O[C@@H]2C[C@H](N(C2)C1=O)C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female, at least 18 years of age at time of Screening.

          2. Screening laboratory result indicating Hepatitis C virus (HCV) genotype (GT)1-, 2-,
             3-, 4-, 5-, or 6-infection.

          3. Subject has positive anti-HCV antibody (Ab) and plasma HCV ribonucleic acid (RNA)
             viral load greater than or equal to 1000 IU/mL at Screening visit.

          4. Subjects must be HCV treatment-naïve (i.e., subject has never received a single dose
             of any approved or investigational anti-HCV medication) or HCV treatment-experienced
             (subject who has failed prior IFN or pegylated-interferon [pegIFN] with or without
             ribavirin [RBV], or sofosbuvir [SOF] plus RBV with or without pegIFN). GT3 subjects
             must be HCV treatment-naïve. Previous HCV treatment must have been completed greater
             than or equal to 2 months prior to Screening.

          5. Subjects naïve to antiretroviral treatment (ART) must have CD4+ count greater than or
             equal to 500 cells/mm^3 (or CD4+ % greater than or equal to 29%) at Screening; or
             Subjects on a stable ART regimen must have

               -  CD4+ count greater than or equal to 200 cells/mm^3 (or CD4+ % greater than or
                  equal to 14%) at Screening; and

               -  Plasma HIV-1 RNA below lower limit of quantification (LLOQ) at Screening and at
                  least once during the 12 months prior to Screening.

        Exclusion Criteria:

          1. Recent (within 6 months prior to study drug administration) history of drug or alcohol
             abuse that could preclude adherence to the protocol in the opinion of the
             investigator.

          2. Positive test result at Screening for hepatitis B surface antigen (HBsAg).

          3. Positive Human Immunodeficiency virus, type 2 (HIV-2) Ab at Screening.

          4. Receipt of any other investigational or commercially available direct acting anti-HCV
             agents other than sofosbuvir (e.g., telaprevir, boceprevir, simeprevir, paritaprevir,
             grazoprevir, daclatasvir, ledipasvir, ombitasvir, elbasvir or dasabuvir).

          5. Consideration by the investigator, for any reason, that the subject is an unsuitable
             candidate to receive ABT-493/ABT-530.
Clinical trial NCT02738333 (phase 3, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: ldv/sof, sof, rbv
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Chronic genotype 2 HCV-infected males and non-pregnant/non-lactating females

          -  Aged 20 years or older

          -  Treatment naive or treatment experienced

          -  At least 20 subjects will have Child-Pugh-A compensated cirrhosis. In Cohort 2,
             participants must be ineligible or intolerant of RBV.

        Key Exclusion Criteria:

          -  Previous exposure to an NS5A or NS5B inhibitor

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  Pregnant or nursing female or male with pregnant female partner

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02739984 (phase 3, status: completed)
Conditions: hypercholesterolemia, mixed dyslipidemia, type 2 diabetes
ICD codes: E78.01, E78.00, Z83.42, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo to evolocumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female ≥ 18 years

          -  Type 2 Diabetes Mellitus

          -  Hemoglobin A1c < 10%

          -  Stable diabetes therapy

          -  Must be on maximally tolerated dose of statin of at least moderate Intensity

          -  Fasting triglycerides ≤ 600 mg/dL

          -  Not at LDL-C or Non-HDL-C goal.

        Exclusion Criteria:

          -  Moderate to severe renal dysfunction

          -  Uncontrolled hypertension

          -  Persistent active liver disease or hepatic dysfunction

          -  Has taken a cholesterylester transfer protein inhibitor in the last 12 months,

          -  Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary
             artery bypass graft or stroke within 3 months prior to randomization